Search

Your search keyword '"Saha, Sarama"' showing total 174 results
Start Over Author "Saha, Sarama"
174 results on '"Saha, Sarama"'

30. LOW DOSE (ICMR) HYDROXYCHLOROQUINE PROPHYLAXIS FOR COVID-19 FAILS -- A PROPHYLAXIS FOR COVID-19 FAILS -- A.

Author

Agarwal, Mayank, Ranka, Rajat, Panda, Prasan Kumar, Kumar, Ajay, Chikara, Gaurav, Sharma, Suresh K., Negi, Rizu, Samanta, Ramanuj, Walia, Rohit, Bahurupi, Yogesh Arvind, Saha, Sarama, Dhar, Minakshi, Sharma, Prakhar, Gupta, Arvind Kumar, Mishra, U. B., Gupta, Manoj Kumar, and Kant, Ravi

Subjects
MEDICAL personnel, COVID-19, HYDROXYCHLOROQUINE, DEVELOPING countries, COVID-19 pandemic
Abstract

Since the COVID-19 pandemic, the world began a frantic search for possible prophylactic 11 options. We conducted a study to assess the role of hydroxychloroquine for COVID-19 12 prophylaxis in health-care workers. The study was a prospective cohort with four arms (high, 13 medium, low dose, and control) of HCQ prophylaxis. Participants were grouped as per their 14 opting for any one arm on a voluntary basis as per institute policy. The outcomes studied 15 were COVID-19 positivity by RT-PCR and its severity assessed by WHO COVID-19 16 severity scale. Total 486 participants were enrolled, of which 29 (6%) opted for low dose, 2 17 (<1%) medium dose, and none for high dose HCQ while 455 (93.6%) were in the control 18 arm. Of the 164 participants who underwent RT-PCR, 96 (58.2%) tested positive. Out of 19 these 96 positive cases, 79 [82.3%]) were ambulatory and were managed conservatively at 20 home. Only 17.7% participants, all from the control group, required hospitalization with the 21 mild-moderate disease. None of the participants had severe disease, COVID-related 22 complications, ICU stay, or death. The difference in the outcome was statistically 23 insignificant (p value >0.05). This single-centre study demonstrated that HCQ prophylaxis in 24 healthcare workers does not cause a significant reduction in COVID-19 as well as mitigating 25 its severity in those infected. At present, most of the trials have not shown any benefit. 26 Though COVID-19 vaccines have reduced the need for prophylaxis, the search for a safe and 27 reasonable chemoprophylaxis should continue until a large population of individuals gets 28 vaccinated, especially in underdeveloped countries. [ABSTRACT FROM AUTHOR]

Published
2022

33. Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19

Author

Panda, Prasan Kumar, primary, Singh, Budha O, additional, Moirangthem, Bikram, additional, Bahurupi, Yogesh Arvind, additional, Saha, Sarama, additional, Saini, Girraj, additional, Dhar, Minakshi, additional, Bairwa, Mukesh, additional, Pai, Venkatesh Srinivasa Pai, additional, Agarwal, Ankit, additional, Sindhwani, Girish, additional, Handu, Shailendra, additional, and Kant, Ravi, additional

Published
2021
Full Text
View/download PDF

34. Single-Point Insulin Sensitivity Estimator (SPISE) as a Feasible Marker of Insulin Resistance in Adult Metabolic Syndrome: Evaluated in a Hospital Based Cross-Sectional Pilot Study at Tertiary Care Centre of Uttarakhand

Author

Rabari, Kamlesh, primary, Naithani, Manisha, additional, Patra, Priyanka, additional, Sonagara, Nikhil, additional, Dudi, Parmila, additional, Goyal, Bela, additional, Saha, Sarama, additional, Mirza, Anissa Atif, additional, and Darbari, Anshuman, additional

Published
2021
Full Text
View/download PDF

35. Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19

Author

Panda,Prasan Kumar, Singh,Budha O, Moirangthem,Bikram, Bahurupi,Yogesh Arvind, Saha,Sarama, Saini,Girraj, Dhar,Minakshi, Bairwa,Mukesh, Pai,Venkatesh Srinivasa Pai, Agarwal,Ankit, Sindhwani,Girish, Handu,Shailendra, Kant,Ravi, Panda,Prasan Kumar, Singh,Budha O, Moirangthem,Bikram, Bahurupi,Yogesh Arvind, Saha,Sarama, Saini,Girraj, Dhar,Minakshi, Bairwa,Mukesh, Pai,Venkatesh Srinivasa Pai, Agarwal,Ankit, Sindhwani,Girish, Handu,Shailendra, and Kant,Ravi

Abstract

Prasan Kumar Panda,1 Budha O Singh,1 Bikram Moirangthem,1 Yogesh Arvind Bahurupi,2 Sarama Saha,3 Girraj Saini,4 Minakshi Dhar,1 Mukesh Bairwa,1 Venkatesh Srinivasa Pai,1 Ankit Agarwal,5 Girish Sindhwani,6 Shailendra Handu,7 Ravi Kant8 1Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 2Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 3Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 4Department of Nursing, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 5Department of Critical Care Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 6Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 7Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India; 8Department of General Surgery, All India Institute of Medical Sciences (AIIMS), Rishikesh, IndiaCorrespondence: Prasan Kumar PandaDepartment of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Sixth Floor, College Block, Rishikesh, 249203, IndiaTel +91 9868999488Email motherprasanna@rediffmail.comPurpose: Definitive antiviral treatment is not available for COVID-19 infection, with the exception of remdesivir, which still evokes many doubts. Various monotherapy or combination therapies with antivirals or other agents have been tried. The present study aims to evaluate the therapeutic potential of hydroxychloroquine and lopinavir–ritonavir in combination with ribavirin in mild–severe COVID-19.Patients and Methods: A single-center, open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic potential of combination antiviral therapies. Enrolled patients in the severe category were randomized into three groups: (A) standard treatment, (B) hydroxychloroq

Published
2021

41. Predictive Value of Beclin1 in the Pathogenesis of Rheumatoid Arthritis in the Indian Population.

Author

Varshney, Tanu, Singh, Praveen, Saha, Sarama, Manna, Sukdev, Pai, Venkatesh, Naithani, Manisha, and Mirza, Anissa

Subjects
PROTEINS, BIOMARKERS, PILOT projects, STATISTICS, PREDICTIVE tests, SCIENTIFIC observation, AUTOPHAGY, MANN Whitney U Test, COMPARATIVE studies, RHEUMATOID arthritis, DESCRIPTIVE statistics, ENZYME-linked immunosorbent assay, MESSENGER RNA, GENE expression profiling, RESEARCH funding, RADIOTHERAPY, DATA analysis software, RECEIVER operating characteristic curves, SENSITIVITY & specificity (Statistics), DATA analysis
Abstract

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease leading to the destruction of articular cartilage and deformity of joints if not detected early. There is an unmet need to find out a highly sensitive and specific biomarker for RA. This was the first study designed in Indian setting to assess whether it can be used as a biomarker in the diagnosis of RA in the Indian population. Aim: To correlate serum Beclin1 in the pathogenesis of rheumatoid arthritis in the Indian population. Patients and Methods: Observational analytical study was conducted for 18 months at AIIMS Rishikesh, Department of Biochemistry in collaboration with the Department of Rheumatology. Beclin1 serum expression levels were estimated by the enzyme-linked immunosorbent assay and beclin1 mRNA expression was assessed by a real-time polymerase chain reaction from peripheral blood mononuclear cells (PBMCs). Beclin1 expression was compared by Mann–Whitney U-test using SPSS 22 version. Cut-off values of Beclin1 for screening of cases were analysed by receiver operating characteristic test. Results: Age- and sex-matched 38 RA patients (5 males and 33 females) and 39 controls (8 males and 31 females) were recruited in the study. Patients with the American College of Rheumatology/European League Against Rheumatism score ≥6 were recruited in this study. Serum level of beclin1 was significantly (P ≤ 0.001) lower in cases (6.30 [2.82]) compared to healthy controls (11.43 [4.62]) which were corroborated with mRNA expression. The optimal cut-off value for detecting RA cases was 7.25 with 89.7% sensitivity and 79.8% specificity. Conclusion: Beclin1 may be involved in the pathogenesis of RA and may be considered a diagnostic marker for RA cases. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results